JOYY heads into its August 28 earnings report with a striking analyst move as the backdrop: JP Morgan nearly tripling its price target on the stock, even as short sellers quietly rebuild positions.
The most notable development this week is the JP Morgan action filed today. Daniel Chen maintained his Overweight rating but raised the price target from $35 to $98 — a move that far exceeds the stock's current $73.41 price and sits well above the consensus mean of $81.08. That target jump is aggressive enough to reshape the bull thesis. UBS initiated at Buy with an $80 target back in March, and Citigroup has been steadily nudging its Buy target higher over the past year. The overall picture is a Street that leans constructive, with three Outperform-equivalent ratings and implied upside of roughly 10% to the consensus target — though the JP Morgan revision alone would imply considerably more.
Short positioning tells a quieter story than the headline numbers suggest. Shorts have risen about 11% over the past week to roughly 2.1% of the free float — low in absolute terms, though the directional move is worth noting ahead of earnings. Borrowing conditions offer no signal of conviction: cost to borrow has actually fallen 25% over the week to just 0.36%, among the lowest levels of the past 30 days. And the borrow market is exceptionally loose — availability dwarfs the current short position, with over 10 million shares available against roughly 1 million shorted. The days-to-cover of 3.5 keeps a theoretical squeeze scenario alive in a hot-print scenario, but there is no structural pressure here. The ORTEX short score has nudged up from 35.8 to 37.9 across the past week, a mild acceleration rather than a meaningful escalation.
Options traders are not particularly defensive heading into the print. The put/call ratio is running at 0.71, slightly below its 20-day average of 0.76, placing it modestly on the bullish side of recent history. That's a meaningful shift from late June and early July, when the ratio was closer to 1.0 to 1.1 — the options market has become noticeably less cautious over the past month as the stock has recovered. The 52-week range for the PCR spans 0.22 to 1.24, so the current reading sits well within normal territory, neither complacent nor alarmed.
The valuation context is worth flagging. JOYY trades at roughly 12x trailing earnings and 0.58x book — unusually cheap for a platform business, and a multiple that has been inching higher over the past month. The EV/EBITDA of 13.3x is modest. The days-to-cover factor scores in the 91st percentile of its universe, a function of thin short interest against a relatively illiquid float. Ownership is highly concentrated: founder Xueling Li holds nearly 38% and Jun Lei a further 12%, leaving relatively limited float for institutional trading. Vanguard Capital Management added a new position as of June 30, while LSV Asset Management added around 231,000 shares — small moves, but consistent with the slowly improving institutional tone.
Earnings history adds another layer of interest. The May 2026 print drove a one-day move of roughly 20% and a five-day move of 26% — an unusually large reaction. The prior event produced a more modest 2.9% next-day gain. With that volatility range in mind, and the JP Morgan target revision landing just 16 days before the August 28 report, the setup into the print is one where the bull case has been loudly restated. Among peers, BILI fell 5.3% on the week and WB dropped 2.6%, suggesting some softness across Chinese internet names broadly — JOYY's own 2% weekly decline tracks roughly in line with that peer drift. What to watch: whether the August 28 earnings print delivers the kind of revenue or margin surprise that would justify the JP Morgan target, and whether the short position — still rebuilding — accelerates or reverses on the day of the release.
See the live data behind this article on ORTEX.
Open JOYY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
